Pilot Study of Ifosfamide/carboplatin/etoposide (ICE) for Peripheral Blood Stem Cell Mobilization in Patients with High-risk or Relapsed Medulloblastoma

Overview

Journal Childs Nerv Syst

Specialty Pediatrics

Date 2007 Jan 18

PMID 17226035

Citations 5

Authors

Shuichi Okada

Teruaki Hongo

Kimiyoshi Sakaguchi

Kazunori Suzuki

Shigeru Nishizawa

Takehiko Ohzeki

Affiliations

Soon will be listed here.

Abstract

Objectives: The purpose of this study is to evaluate the stem cell mobilization capacity, anti-tumor effect, and feasibility of ifosfamide/carboplatin/etoposide (ICE) for transplant-eligible patients with medulloblastoma.

Materials And Methods: Six patients (23 months to 18 years old) with high-risk or relapsed medulloblastoma received one cycle of ICE, which consisted of ifosfamide at 1.8 g/m(2) for 5 days, carboplatin 400 mg/m(2) for 2 days, and etoposide 100 mg/m(2) for 5 days. Stem cells were mobilized with ICE followed by granulocyte colony-stimulating factor at 10 microg kg(-1) day(-1).

Results: After one cycle of ICE, the median number of harvested CD34+ cells per apheresis session was 11.85 x 10(6) cells/kg (range, 0.2 to 71.2 x 10(6) cells/kg). Two patients obtained a complete response and three patients a partial response. All patients experienced severe myelosuppression, and three infectious toxicities were observed.

Conclusions: These results suggest that ICE is optimal for mobilizing stem cells, effective for high-risk or relapsed medulloblastoma, and tolerable with limited non-hematological toxicity.

Citing Articles

Outcomes of five cases of retinoblastoma with optic nerve invasion on imaging.

Onishi T, Nishina S, Yokoi T, Yoshida T, Hayashi S, Morikawa-Anzai H Jpn J Ophthalmol. 2024; 68(6):741-750.

PMID: 39340727 PMC: 11607017. DOI: 10.1007/s10384-024-01112-z.

Hypofractionated radiotherapy combined with bevacizumab plus low-dose ifosfamide, carboplatin, and etoposide as second-line chemoradiotherapy for progressing spinal diffuse midline glioma, H3K27-altered: illustrative case.

Nakayasu S, Tanji M, Uto M, Takeuchi Y, Makino Y, Hattori E J Neurosurg Case Lessons. 2024; 8(7).

PMID: 39133948 PMC: 11323846. DOI: 10.3171/CASE2464.

Impact of treatment and clinical characteristics on the survival of children with medulloblastoma in Mexico.

Salceda-Rivera V, Tejocote-Romero I, Osorio D, Bellido-Magana R, Lopez-Facundo A, Anaya-Aguirre S Front Oncol. 2024; 14:1376574.

PMID: 38756654 PMC: 11096484. DOI: 10.3389/fonc.2024.1376574.

The use of Sonidegib in the adjuvant and advanced phases of Sonic Hedge Hog Mutant Medulloblastomas.

Yuile A, Kastelan M, Lee A, Back M, Drummond J, Wheeler H Oxf Med Case Reports. 2022; 2022(3):omac019.

PMID: 35316996 PMC: 8931813. DOI: 10.1093/omcr/omac019.

Pediatric brain tumors: current treatment strategies and future therapeutic approaches.

Mueller S, Chang S Neurotherapeutics. 2009; 6(3):570-86.

PMID: 19560746 PMC: 5084192. DOI: 10.1016/j.nurt.2009.04.006.

References

Zeltzer P, Boyett J, Finlay J, Albright A, RORKE L, Milstein J . Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol. 1999; 17(3):832-45. DOI: 10.1200/JCO.1999.17.3.832. View

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

Sanson M, Ameri A, Monjour A, Sahmoud T, Ronchin P, Poisson M . Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study. Eur J Cancer. 1996; 32A(13):2229-35. DOI: 10.1016/s0959-8049(96)00299-7. View

Krailo M, Goldman S, Slack R, Davenport V, Morris E, Laver J . Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report. Ann Oncol. 2002; 13(3):460-9. DOI: 10.1093/annonc/mdf028. View

Kobrinsky N, Packer R, Boyett J, Stanley P, Allen J, Garvin J . Etoposide with or without mannitol for the treatment of recurrent or primarily unresponsive brain tumors: a Children's Cancer Group Study, CCG-9881. J Neurooncol. 2000; 45(1):47-54. DOI: 10.1023/a:1006333811437. View

Heideman R, Kovnar E, Kellie S, Douglass E, Gajjar A, Walter A . Preirradiation chemotherapy with carboplatin and etoposide in newly diagnosed embryonal pediatric CNS tumors. J Clin Oncol. 1995; 13(9):2247-54. DOI: 10.1200/JCO.1995.13.9.2247. View

Zelenetz A, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz C . Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol. 2003; 14 Suppl 1:i5-10. DOI: 10.1093/annonc/mdg702. View

Van Winkle P, Angiolillo A, Krailo M, Cheung Y, Anderson B, Davenport V . Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. Pediatr Blood Cancer. 2004; 44(4):338-47. DOI: 10.1002/pbc.20227. View

Rood B, MacDonald T, Packer R . Current treatment of medulloblastoma: recent advances and future challenges. Semin Oncol. 2004; 31(5):666-75. DOI: 10.1053/j.seminoncol.2004.07.009. View

10.

Gardner S . Application of stem cell transplant for brain tumors. Pediatr Transplant. 2004; 8 Suppl 5:28-32. DOI: 10.1111/j.1398-2265.2004.00202.x. View

11.

Kuhl J, Muller H, Berthold F, Kortmann R, Deinlein F, Maass E . Preradiation chemotherapy of children and young adults with malignant brain tumors: results of the German pilot trial HIT'88/'89. Klin Padiatr. 1998; 210(4):227-33. DOI: 10.1055/s-2008-1043883. View

12.

Gerke P, Filejski W, Robins H, Wiedemann G, Steinhoff J . Nephrotoxicity of ifosfamide, carboplatin and etoposide (ICE) alone or combined with extracorporeal or radiant-heat-induced whole-body hyperthermia. J Cancer Res Clin Oncol. 2000; 126(3):173-7. DOI: 10.1007/s004320050028. View

13.

Skinner R . Chronic ifosfamide nephrotoxicity in children. Med Pediatr Oncol. 2003; 41(3):190-7. DOI: 10.1002/mpo.10336. View

14.

Taylor R, Bailey C, Robinson K, Weston C, Walker D, Ellison D . Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. Eur J Cancer. 2005; 41(5):727-34. DOI: 10.1016/j.ejca.2004.12.017. View

15.

Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C . Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol. 2000; 18(6):1360-77. DOI: 10.1200/JCO.2000.18.6.1360. View

16.

Packer R, Goldwein J, Nicholson H, Vezina L, Allen J, Ris M . Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. J Clin Oncol. 1999; 17(7):2127-36. DOI: 10.1200/JCO.1999.17.7.2127. View

17.

Mastrangelo R, Lasorella A, Riccardi R, Colosimo C, Iavarone A, Tornesello A . Carboplatin in childhood medulloblastoma/PNET: feasibility of an in vivo sensitivity test in an "up-front" study. Med Pediatr Oncol. 1995; 24(3):188-96. DOI: 10.1002/mpo.2950240309. View

18.

Fruehauf S, Seggewiss R . It's moving day: factors affecting peripheral blood stem cell mobilization and strategies for improvement [corrected]. Br J Haematol. 2003; 122(3):360-75. DOI: 10.1046/j.1365-2141.2003.04483.x. View

19.

Sezer O, Possinger K, Metzner B, Illiger H, Wattad M, Heit W . Optimal CD34(+) cell dose in autologous peripheral-blood stem-cell transplantation. J Clin Oncol. 2000; 18(18):3319-20. DOI: 10.1200/JCO.2000.18.18.3319. View

20.

Moskowitz C, Bertino J, Glassman J, Hedrick E, Hunte S, Agus D . Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol. 1999; 17(12):3776-85. DOI: 10.1200/JCO.1999.17.12.3776. View